<p>在欧洲市场情绪改善的背景下，泛欧 STOXX 欧洲 600 指数在美国与伊朗达成停火协议后显著上涨 3.05%，增强了该地区投资者的信心。尽管经济不确定性依然存在，增长预测可能会被下调，各个行业发出的信号也不尽相同，投资者越来越倾向于寻找能够平衡风险与收益的机会。虽然 “便士股票” 这个术语可能显得过时，但它仍然指向那些较小或较新的公司，这些公司在强大的财务支持下能够提供显著的价值。本文探讨了三只在当今市场环境中因财务韧性和增长潜力而脱颖而出的欧洲便士股票。</p>
<h3>欧洲十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Ariston Holding (BIT:ARIS)</td>
<td>€3.922</td>
<td>€1.36B</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (DB:0QM)</td>
<td>€0.31</td>
<td>€239.95M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Verkkokauppa.com Oyj (HLSE:VERK)</td>
<td>€3.345</td>
<td>€150.79M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Nurminen Logistics Oyj (HLSE:NLG1V)</td>
<td>€0.878</td>
<td>€70.89M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>High (ENXTPA:HCO)</td>
<td>€3.77</td>
<td>€73.07M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Deceuninck (ENXTBR:DECB)</td>
<td>€2.145</td>
<td>€296.54M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Eniro Group (OM:ENRO)</td>
<td>SEK0.698</td>
<td>SEK508.15M</td>
<td>✅ 1 ⚠️ 4 查看分析 </td>
</tr>
<tr>
<td>Netgem (ENXTPA:ALNTG)</td>
<td>€0.74</td>
<td>€24.78M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Pharming Group (ENXTAM:PHARM)</td>
<td>€1.453</td>
<td>€1.03B</td>
<td>✅ 5 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
<p>点击这里查看我们欧洲便士股票筛选器中的 277 只股票的完整列表。</p>
<p>让我们从我们的专业筛选器中发现一些宝藏。</p>
<h2>Sinteza (BVB:STZ)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Sinteza S.A.是一家罗马尼亚公司，专注于基本有机化学产品的生产、营销和销售，市值为 RON38.21 百万。</p>
<p><strong>运营：</strong> 公司的收入主要来自其他有机基本化学品的制造，总计为 RON0.39 百万。</p>
<p><strong>市值：</strong> RON38.21M</p>
<p>Sinteza S.A.是一家罗马尼亚公司，目前尚未产生收入，销售额为 RON 0.39 百万，面临短期资产为 RON 2.9 百万无法覆盖总负债 RON 10.6 百万的挑战。尽管处于亏损状态，该公司已将净亏损从 RON 8.78 百万改善至 RON 3.44 百万，并因每年超过 21% 的自由现金流增长而保持超过三年的现金储备。Sinteza 无债务，交易价格显著低于其估计的公允价值，但缺乏经验丰富的管理数据，并且与行业标准相比，盈利增长面临波动。</p>
<ul>
<li>解锁我们对 Sinteza 股票分析的全面见解，查看此财务健康报告。</li>
<li>通过访问我们的历史表现报告，评估 Sinteza 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6dab6e8f-d263-4249-8f13-06f27245c0d4/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6dab6e8f-d263-4249-8f13-06f27245c0d4/chart/financial-position-analysis"/></p>
<p>BVB:STZ 财务状况分析截至 2026 年 4 月</p>
<h2>IDL Diagnostics (OM:IDLDX)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> IDL Diagnostics AB (publ) 是一家总部位于瑞典的体外诊断公司，制造和销售用于肿瘤和细菌疾病的 IVD 测试，市值为 SEK78.32 百万。</p>
<p><strong>运营：</strong> 公司的收入主要来自其细菌学部门，贡献 SEK29.58 百万，其次是肿瘤学部门贡献 SEK23.46 百万。</p>
<p><strong>市值：</strong> SEK78.32M</p>
<p>IDL Diagnostics AB 是一家瑞典体外诊断公司，尽管面临挑战，但展现出韧性。2025 年报告销售额为 SEK 53.11 百万，细菌学部门在收入生成中占主导地位。该公司仍处于亏损状态，净亏损为 SEK 12.15 百万，但在过去五年中每年减少亏损 0.8%，并保持超过三年的强劲现金储备，没有债务问题。最近的战略举措包括与 concile GmbH 成立合资企业，以扩大其快速测试的市场覆盖，可能在高管变动期间增强未来的收入来源，因为首席执行官 Anders Hultman 离职。</p>
<ul>
<li>点击探索我们在 IDL Diagnostics 财务健康报告中的详细发现。</li>
<li>在我们的增长报告中查看 IDL Diagnostics 的分析师预测。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23e3e2c3-0cb5-463c-a9d4-fc907abbe900/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23e3e2c3-0cb5-463c-a9d4-fc907abbe900/chart/debt-equity-history-analysis"/></p>
<p>OM:IDLDX 债务与股本历史及分析截至 2026 年 4 月</p>
<h2>Dr. Miele Cosmed Group (WSE:DMG)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Dr. Miele Cosmed Group S.A.在波兰及国际市场上生产和销售化学及化妆品产品，市值为 PLN246.29 百万。</p>
<p><strong>运营：</strong> 该公司从化妆品、卫生和家庭化学产品的生产中获得 PLN501.04 百万的收入。</p>
<p><strong>市值：</strong> PLN246.29M</p>
<p>Dr. Miele Cosmed Group S.A.展现出财务稳定性，短期资产（PLN144.5M）覆盖短期（PLN143M）和长期负债（PLN26.4M）。该公司的债务与股本比率在五年内从 28.2% 降低至 19.3%，表明财务健康改善，运营现金流覆盖 77.3% 的债务义务，尽管最近的盈利增长为负（-32.7%），但现金管理效率良好。然而，利润率从 7.4% 下降至 4.8%，公司的股本回报率仍然较低，为 9%。该股票的交易价格显著低于估计的公允价值，可能在这些混合信号中提供投资吸引力。</p>
<ul>
<li>点击这里访问我们完整的财务健康分析报告，以了解 Dr. Miele Cosmed Group 的动态。</li>
<li>通过我们的详细历史业绩报告评估 Dr. Miele Cosmed Group 的过去业绩。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d836070b-f300-4a22-b868-5c9895e67282/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d836070b-f300-4a22-b868-5c9895e67282/chart/debt-equity-history-analysis"/></p>
<p>WSE:DMG 债务与股本历史及分析截至 2026 年 4 月</p>
<h2>抓住机会</h2>
<ul>
<li>点击此链接访问 277 只欧洲便士股票的完整范围。</li>
<li>对其他选择感兴趣？发现 10 家在 COVID 后生存并蓬勃发展的公司，它们具备应对特朗普关税的正确要素。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
<p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

L6EW

XSER

DJMC

欧洲精选高股利指数 STOXX ETF - First Trust

DJSC

<p>泛欧 STOXX 欧洲 600 指数在美国与伊朗停火后，市场情绪改善，上涨了 3.05%。投资者正在关注便士股票，这些股票代表了具有潜在价值的小型公司。本文重点介绍了三只欧洲便士股票：Sinteza、IDL Diagnostics 和 Dr. Miele Cosmed Group，尽管面临挑战，但它们各自展现了财务韧性。Sinteza 尚未产生收入，但其净亏损有所改善；IDL Diagnostics 减少了亏损并成立了合资企业；而 Dr. Miele Cosmed Group 尽管利润率下降，但仍显示出财务稳定性。鼓励投资者在当前市场环境中探索这些机会</p>

<p>Amid improving market sentiment in Europe, the pan-European STOXX Europe 600 Index saw a notable rise of 3.05% following a U.S.-Iran ceasefire agreement, boosting investor confidence across the region. As economic uncertainties linger with potential cuts to growth forecasts and mixed signals from various sectors, investors are increasingly seeking opportunities that balance risk and reward. While the term &#34;penny stock&#34; might seem outdated, it still points to smaller or newer companies that can offer significant value when backed by strong financials. This article explores three European penny stocks that stand out for their financial resilience and potential for growth in today's market landscape.</p>
<div class="lb-trans"><p>在欧洲市场情绪改善的背景下，泛欧 STOXX 欧洲 600 指数在美国与伊朗达成停火协议后显著上涨 3.05%，增强了该地区投资者的信心。尽管经济不确定性依然存在，增长预测可能会被下调，各个行业发出的信号也不尽相同，投资者越来越倾向于寻找能够平衡风险与收益的机会。虽然 “便士股票” 这个术语可能显得过时，但它仍然指向那些较小或较新的公司，这些公司在强大的财务支持下能够提供显著的价值。本文探讨了三只在当今市场环境中因财务韧性和增长潜力而脱颖而出的欧洲便士股票。</p>
</div><h3>Top 10 Penny Stocks In Europe</h3>
<div class="lb-trans"><h3>欧洲十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Ariston Holding (BIT:ARIS)</td>
<td>€3.922</td>
<td>€1.36B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Angler Gaming (DB:0QM)</td>
<td>€0.31</td>
<td>€239.95M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Verkkokauppa.com Oyj (HLSE:VERK)</td>
<td>€3.345</td>
<td>€150.79M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Nurminen Logistics Oyj (HLSE:NLG1V)</td>
<td>€0.878</td>
<td>€70.89M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>High (ENXTPA:HCO)</td>
<td>€3.77</td>
<td>€73.07M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Deceuninck (ENXTBR:DECB)</td>
<td>€2.145</td>
<td>€296.54M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Eniro Group (OM:ENRO)</td>
<td>SEK0.698</td>
<td>SEK508.15M</td>
<td>✅ 1 ⚠️ 4 View Analysis &gt;</td>
</tr>
<tr>
<td>Netgem (ENXTPA:ALNTG)</td>
<td>€0.74</td>
<td>€24.78M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Pharming Group (ENXTAM:PHARM)</td>
<td>€1.453</td>
<td>€1.03B</td>
<td>✅ 5 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Ariston Holding (BIT:ARIS)</td>
<td>€3.922</td>
<td>€1.36B</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (DB:0QM)</td>
<td>€0.31</td>
<td>€239.95M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Verkkokauppa.com Oyj (HLSE:VERK)</td>
<td>€3.345</td>
<td>€150.79M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Nurminen Logistics Oyj (HLSE:NLG1V)</td>
<td>€0.878</td>
<td>€70.89M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>High (ENXTPA:HCO)</td>
<td>€3.77</td>
<td>€73.07M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Deceuninck (ENXTBR:DECB)</td>
<td>€2.145</td>
<td>€296.54M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Eniro Group (OM:ENRO)</td>
<td>SEK0.698</td>
<td>SEK508.15M</td>
<td>✅ 1 ⚠️ 4 查看分析 </td>
</tr>
<tr>
<td>Netgem (ENXTPA:ALNTG)</td>
<td>€0.74</td>
<td>€24.78M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Pharming Group (ENXTAM:PHARM)</td>
<td>€1.453</td>
<td>€1.03B</td>
<td>✅ 5 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 277 stocks from our European Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们欧洲便士股票筛选器中的 277 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>让我们从我们的专业筛选器中发现一些宝藏。</p>
</div><h2>Sinteza (BVB:STZ)</h2>
<div class="lb-trans"><h2>Sinteza (BVB:STZ)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Sinteza S.A. is a Romanian company involved in the production, marketing, and sale of basic organic chemical products, with a market capitalization of RON38.21 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Sinteza S.A.是一家罗马尼亚公司，专注于基本有机化学产品的生产、营销和销售，市值为 RON38.21 百万。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from the manufacture of other organic basic chemicals, totaling RON0.39 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其他有机基本化学品的制造，总计为 RON0.39 百万。</p>
</div><p><strong>Market Cap:</strong> RON38.21M</p>
<div class="lb-trans"><p><strong>市值：</strong> RON38.21M</p>
</div><p>Sinteza S.A., a Romanian company, remains pre-revenue with sales of RON 0.39 million and faces challenges with short-term assets of RON 2.9 million not covering liabilities totaling RON 10.6 million. Despite being unprofitable, the company has improved its net loss from RON 8.78 million to RON 3.44 million year-over-year and maintains a sufficient cash runway for over three years due to positive free cash flow growth of over 21% annually. Sinteza is debt-free, trading significantly below its estimated fair value, but lacks seasoned management data and faces volatility in earnings growth compared to industry standards.</p>
<div class="lb-trans"><p>Sinteza S.A.是一家罗马尼亚公司，目前尚未产生收入，销售额为 RON 0.39 百万，面临短期资产为 RON 2.9 百万无法覆盖总负债 RON 10.6 百万的挑战。尽管处于亏损状态，该公司已将净亏损从 RON 8.78 百万改善至 RON 3.44 百万，并因每年超过 21% 的自由现金流增长而保持超过三年的现金储备。Sinteza 无债务，交易价格显著低于其估计的公允价值，但缺乏经验丰富的管理数据，并且与行业标准相比，盈利增长面临波动。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Sinteza stock in this financial health report.</li>
<li>Evaluate Sinteza's historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对 Sinteza 股票分析的全面见解，查看此财务健康报告。</li>
<li>通过访问我们的历史表现报告，评估 Sinteza 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6dab6e8f-d263-4249-8f13-06f27245c0d4/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/6dab6e8f-d263-4249-8f13-06f27245c0d4/chart/financial-position-analysis"/></p>
<p>BVB:STZ Financial Position Analysis as at Apr 2026</p>
<div class="lb-trans"><p>BVB:STZ 财务状况分析截至 2026 年 4 月</p>
</div><h2>IDL Diagnostics (OM:IDLDX)</h2>
<div class="lb-trans"><h2>IDL Diagnostics (OM:IDLDX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> IDL Diagnostics AB (publ) is a vitro diagnostics company based in Sweden that manufactures and sells IVD tests for oncological and bacterial diseases, with a market cap of SEK78.32 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> IDL Diagnostics AB (publ) 是一家总部位于瑞典的体外诊断公司，制造和销售用于肿瘤和细菌疾病的 IVD 测试，市值为 SEK78.32 百万。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily generated from its Bacteriology segment, which accounts for SEK29.58 million, followed by the Oncology segment at SEK23.46 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其细菌学部门，贡献 SEK29.58 百万，其次是肿瘤学部门贡献 SEK23.46 百万。</p>
</div><p><strong>Market Cap:</strong> SEK78.32M</p>
<div class="lb-trans"><p><strong>市值：</strong> SEK78.32M</p>
</div><p>IDL Diagnostics AB, a Swedish in vitro diagnostics company, has shown resilience despite challenges. It reported SEK 53.11 million in sales for 2025, with its Bacteriology segment leading revenue generation. The company remains unprofitable with a net loss of SEK 12.15 million but has managed to reduce losses over the past five years by 0.8% annually and maintains a strong cash runway exceeding three years without debt concerns. Recent strategic moves include forming a joint venture with concile GmbH to expand its market reach for rapid tests, potentially enhancing future revenue streams amidst executive transitions as CEO Anders Hultman departs.</p>
<div class="lb-trans"><p>IDL Diagnostics AB 是一家瑞典体外诊断公司，尽管面临挑战，但展现出韧性。2025 年报告销售额为 SEK 53.11 百万，细菌学部门在收入生成中占主导地位。该公司仍处于亏损状态，净亏损为 SEK 12.15 百万，但在过去五年中每年减少亏损 0.8%，并保持超过三年的强劲现金储备，没有债务问题。最近的战略举措包括与 concile GmbH 成立合资企业，以扩大其快速测试的市场覆盖，可能在高管变动期间增强未来的收入来源，因为首席执行官 Anders Hultman 离职。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in IDL Diagnostics' financial health report.</li>
<li>Explore IDL Diagnostics' analyst forecasts in our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 IDL Diagnostics 财务健康报告中的详细发现。</li>
<li>在我们的增长报告中查看 IDL Diagnostics 的分析师预测。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23e3e2c3-0cb5-463c-a9d4-fc907abbe900/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/23e3e2c3-0cb5-463c-a9d4-fc907abbe900/chart/debt-equity-history-analysis"/></p>
<p>OM:IDLDX Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>OM:IDLDX 债务与股本历史及分析截至 2026 年 4 月</p>
</div><h2>Dr. Miele Cosmed Group (WSE:DMG)</h2>
<div class="lb-trans"><h2>Dr. Miele Cosmed Group (WSE:DMG)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Dr. Miele Cosmed Group S.A. produces and sells chemical and cosmetic products both in Poland and internationally, with a market cap of PLN246.29 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Dr. Miele Cosmed Group S.A.在波兰及国际市场上生产和销售化学及化妆品产品，市值为 PLN246.29 百万。</p>
</div><p><strong>Operations:</strong> The company generates revenue of PLN501.04 million from the production of cosmetic, toilet, and household chemistry products.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从化妆品、卫生和家庭化学产品的生产中获得 PLN501.04 百万的收入。</p>
</div><p><strong>Market Cap:</strong> PLN246.29M</p>
<div class="lb-trans"><p><strong>市值：</strong> PLN246.29M</p>
</div><p>Dr. Miele Cosmed Group S.A. demonstrates financial stability with short-term assets (PLN144.5M) covering both short-term (PLN143M) and long-term liabilities (PLN26.4M). The company has reduced its debt to equity ratio from 28.2% to 19.3% over five years, indicating improved financial health, while operating cash flow covers 77.3% of its debt obligations, suggesting efficient cash management despite recent negative earnings growth (-32.7%). However, profit margins have declined from 7.4% to 4.8%, and the company's return on equity remains low at 9%. The stock trades significantly below estimated fair value, potentially offering investment appeal amidst these mixed signals.</p>
<div class="lb-trans"><p>Dr. Miele Cosmed Group S.A.展现出财务稳定性，短期资产（PLN144.5M）覆盖短期（PLN143M）和长期负债（PLN26.4M）。该公司的债务与股本比率在五年内从 28.2% 降低至 19.3%，表明财务健康改善，运营现金流覆盖 77.3% 的债务义务，尽管最近的盈利增长为负（-32.7%），但现金管理效率良好。然而，利润率从 7.4% 下降至 4.8%，公司的股本回报率仍然较低，为 9%。该股票的交易价格显著低于估计的公允价值，可能在这些混合信号中提供投资吸引力。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of Dr. Miele Cosmed Group.</li>
<li>Assess Dr. Miele Cosmed Group's previous results with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们完整的财务健康分析报告，以了解 Dr. Miele Cosmed Group 的动态。</li>
<li>通过我们的详细历史业绩报告评估 Dr. Miele Cosmed Group 的过去业绩。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d836070b-f300-4a22-b868-5c9895e67282/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/d836070b-f300-4a22-b868-5c9895e67282/chart/debt-equity-history-analysis"/></p>
<p>WSE:DMG Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>WSE:DMG 债务与股本历史及分析截至 2026 年 4 月</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Access the full spectrum of 277 European Penny Stocks by clicking on this link.</li>
<li>Curious About Other Options? Uncover 10 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此链接访问 277 只欧洲便士股票的完整范围。</li>
<li>对其他选择感兴趣？发现 10 家在 COVID 后生存并蓬勃发展的公司，它们具备应对特朗普关税的正确要素。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

2026 年 4 月值得关注的欧洲低价股